The expanding field of biological therapy relies heavily on recombinant mediator technology, and a thorough understanding of individual profiles is paramount for fine-tuning experimental design and therapeutic efficacy. Specifically, examining the characteristics of recombinant IL-1A, IL-1B, IL-2, and IL-3 reveals significant differences in their s